Association between phosphatidylinositol 3-kinase regulatory subunit p85α Met326Ile genetic polymorphism and colon cancer risk

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 633-637

  Li, Li ^a,d   Plummer, Sarah J ^b   Thompson, Cheryl L ^a   Tucker, Thomas C ^c   Casey, Graham ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE; METHIONINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SUBUNIT; FAMILY HISTORY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONCOGENE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOKING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SUBSTITUTION; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 38949125150     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1211     Document Type: Article

References (25)

1. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-54.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-10.
3. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183-98.
4. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000;9:283-7.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase/AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
6. Sandhu MS, Dunger DB, Giovannucci E. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biological interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
7. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
8. Brugge J, Hung MC, Mills GB. A new mutational akt-ivation in the PI3K pathway. Cancer Cell 2007;12:104-7.
9. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
10. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-44.
11. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:767-81.
12. Phillips WA, Russell SE, Ciavarella ML, et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 2006;118:2644-6.
13. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
14. Philp AL, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p 85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-9.
15. Luo J, Sobkiw CL, Logsdon NM, et al. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2005;102:10238-43.
16. Almind K, Delahaye L, Hansen T, Van Obberghen E, Pedersen O, Kahn CR. Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85α. Proc Natl Acad Sci US A 2002;99:2124-8.
17. Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and its implication in cancer. Cell Cycle 2005;4:44-7.
18. Paradis AE, Kantoff PW, Giovannucci E, Stampfer MJ, Ma J. Association between the Met326Ile polymorphism of the p85α regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2003;12:172-3.
19. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-9.
20. Taniguchi CM, Tran TT, Kondo T, Ueki K, Cantley LC, Kahn CR. Phosphoinositide 3-kinase regulatory subunit p85a suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci U S A 2006;103:12093-7.
21. Jamshidi Y, Snieder H, Wang X, et al. Phosphatidylinositol 3-kinase p85α regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population. Diabetologia 2006;49:2659-67.
22. Hansen T, Andersen CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85α regulatory subunit of phosphatidylinositol 3-kinase: effect on glucose disappearance constant, glucose effectiveness, and insulin sensitivity index. Diabetes 1997;46:494-501.
23. Hansen L, Zethelius B, Berglund L, et al. In vitro and in vivo studies of a naturally occurring variant of the human p85α regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity. Diabetes 2001;50:690-3.
24. Chen S, Yan W, Huang J, Ge D, Yao Z, Gu D. Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85α) with type 2 diabetes mellitus and hypertension in the Chinese Han population. Diabet Med 2005;22:737-43.
25. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999;91:916-32.